Cyclic peptides are macromolecules with restricted structures that have stronger competitive edges than linear biological entities. They have been reported to possess various activities, such as antifungal, antiviral, and antimicrobial activities.
Key Takeaways
- Cyclic peptides are excellent examples of broad-spectrum antivirals.
- They have a unique conformational constraint that provides a larger surface area to interact with the target.
- Cyclic peptides improve the membrane permeability and in vivo stability compared to their linear counterparts.
- There is emerging interest in cyclic peptide therapeutics.
The Antiviral Activity of Cyclic Peptides
Overview
Cyclic peptides have been found to neutralize a broad range of group 1 influenza A viruses, including H5N1. The peptide design was based on complementarity-determining region (CDR) loops.
Advantages of Cyclic Peptides
The unique conformational constraint of cyclic peptides provides a larger surface area to interact with the target at the same time, improving the membrane permeability and in vivo stability compared to their linear counterparts.
Applications in Antiviral Therapies
Cyclic peptides have been reported to possess various activities, such as antifungal, antiviral, and antimicrobial activities. To date, there is emerging interest in cyclic peptide therapeutics, and increasing numbers of clinically approved cyclic peptide drugs are available on the market.
Cyclic Peptides in Clinical Trials
Current Status
Several cyclic peptides are currently in clinical trials for various diseases, including viral infections. These trials are crucial steps in understanding the safety and efficacy of these potential therapeutics.
Challenges and Solutions
Despite the promising potential of cyclic peptides, there are challenges in their development, such as their synthesis and delivery. However, advancements in peptide engineering and drug delivery technologies are helping to overcome these obstacles.
Future Directions
Potential for Broad-Spectrum Antiviral Agents
Given their unique properties and broad-spectrum antiviral activity, cyclic peptides hold great promise for the future of antiviral therapies. Their ability to target a wide range of viruses makes them particularly valuable in the face of emerging and re-emerging viral diseases.
Advancements in Research
Research in the field of cyclic peptides is rapidly advancing, with new cyclic peptide-based drugs being developed and tested. These advancements are expected to further expand the potential applications of cyclic peptides in antiviral therapy.
Frequently Asked Questions
What are cyclic peptides?
Cyclic peptides are macromolecules with restricted structures that have stronger competitive edges than linear biological entities.
How do cyclic peptides work as antiviral agents?
Cyclic peptides have been found to neutralize a broad range of group 1 influenza A viruses, including H5N1. The peptide design was based on complementarity-determining region (CDR) loops.
What are the advantages of cyclic peptides?
The unique conformational constraint of cyclic peptides provides a larger surface area to interact with the target at the same time, improving the membrane permeability and in vivo stability compared to their linear counterparts.
Are there any cyclic peptide drugs on the market?
Yes, there are increasing numbers of clinically approved cyclic peptide drugs available on the market.
For more information, you can visit LifeTein’s homepage.
Chia, L. Y., Kumar, P. V., Maki, M. A. A., Ravichandran, G., & Thilagar, S. (2022). A Review: The Antiviral Activity of Cyclic Peptides. In International Journal of Peptide Research and Therapeutics (Vol. 29, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1007/s10989-022-10478-y